S. 5244, Drug Program Compliance & Accountability Overhaul. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
S. 5244 · Mixed
What it does
The SUSTAIN 340B Act tightens oversight and accountability in the 340B drug discount program, which allows certain healthcare entities (hospitals, clinics, safety-net providers) to purchase drugs at steep discounts for uninsured and low-income patients. The bill requires covered entities to register contract pharmacies, maintain detailed records, report how they use savings, and submit to audits by HHS and drug manufacturers. It also restricts which patients qualify for the discount, limits how entities can use referral prescriptions, and imposes penalties for violations—including temporary program exclusion and civil fines.
The analysis names pharmaceutical manufacturers (audit rights, data access, ability to challenge eligibility) — and 1 more group — among the beneficiaries.
The trade-off
Narrowing the 'patient' definition (requiring documented outpatient service within 2 years, auditable medical records) may exclude homeless, episodic-care, or highly mobile populations who are among the program's intended beneficiaries.
The analysis put a high warning level on this bill. Transparency scores 65%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Jerry Moran. Cosponsored by John Boozman, John Hickenlooper, Shelley Capito and Tammy Baldwin.